Scilex Holding Company Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Scilex Holding Company (SCLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.57 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-04-10
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.89, a 75.68% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $3.66.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $11.57, a 50.74% decline from fiscal 2024.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $23.49, a 625.00% increase from fiscal 2023.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.24.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $11.57 10-K · filed 2026-04-10 | ||||
| 2025-09-30 | $12.94 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $3.76 10-Q · filed 2025-08-13 | ||||
| 2024-12-31 | $23.49 10-K · filed 2026-04-10 | $0.67 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $0.81 10-Q · filed 2025-01-17 | ||||
| 2024-06-30 | $0.77 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $0.89 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $3.24 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $3.66 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $3.66 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | $3.66 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |